GV was among the investors as long-term care support provider CareBridge emerged from stealth with $40m and two acquisitions.

The logistics company has received $11m in a series A extension, bringing the Sinar Mas-backed round to $25.5m.

CareCentrix, Nationwide and existing backer Kaiser Permanente all chipped in as the homecare support services provider secured $30m.

Antiviral drug maker Gilead is among the investors that have backed the cell therapy startup’s $25m round.

GV and Nextech are among the participants in a series A round that is funding the launch of EQRx, which is developing cheaper copies of existing drugs.

The remittance services startup raised $31.2m from backers including HashKey, UOB, Seven Bank, Uni-President Enterprises and Hanwha.

Jasper Therapeutics, based in part on Stanford research, has raised a $15m series A extension on the back of early clinical results from its blood transplant conditioning program.

Mayo Clinic has bet on chronic disease drug developer Novome Biotechnologies, which is initially targeting a disorder known as hyperoxaluria.

Roche Venture Fund led a $14.1m extension for Jasper Therapeutics, developer of a conditioning agent for haematopoietic cell transplants, boosting the round to more than $49m.

Monex featured in a $17.7m round for Securrency to help the blockchain technology developer take its total funding to $20m.